Agios Pharmaceuticals, Inc.
AGIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 3.4% | 42.7% | -18.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 87% | 76.2% | 87.6% | 88.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -792.4% | -889.3% | -1,207.3% | -1,152.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -803.1% | -899.4% | -1,023.3% | -899.6% |
| EPS Diluted | -1.78 | -1.93 | -1.55 | -1.69 |
| % Growth | 7.8% | -24.5% | 8.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |